UGT1A1

Drugs affected by UGT1A1

UDP Glucuronosyltransferase Family 1 Member A1

6 medications 9 brand products

About UGT1A1

UGT1A1 clears bilirubin (the molecule that builds up in jaundice) and several drugs including irinotecan and nilotinib. A variant called *28, common in people of all ancestries, reduces UGT1A1 activity. It's the cause of Gilbert's syndrome, a benign condition, but it also makes cancer patients much more susceptible to severe side effects from irinotecan-based chemotherapy.

Oncology dosing of irinotecan is often adjusted down for patients carrying two copies of the UGT1A1*28 variant.

Medications with UGT1A1 guidelines

Gene2Rx covers 6 medications with published pharmacogenetic guidance for UGT1A1, drawn from CPIC and FDA sources. Each drug links to its full pharmacogenetics page.

antiretrovirals

Atazanavir CPIC

chemotherapies →

Belinostat FDA Irinotecan FDA Nilotinib FDA Pazopanib FDA Sacituzumab Govitecan Hziy FDA

Brand products containing a UGT1A1-affected ingredient

These branded medications include at least one active ingredient whose metabolism or action involves UGT1A1. Each links to its full pharmacogenetic breakdown.

sacituzumab govitecan-hziy

Votrient

pazopanib

Find out your personal UGT1A1 phenotype

This page lists drugs affected by UGT1A1. A Gene2Rx report tells you which metabolizer group you fall into, and what that means for every medication on this list.

Get your report Look up a medication

Informational only, not medical advice. The presence of a UGT1A1 pharmacogenetic guideline does not mean every patient needs to change their dose. Never start, stop, or change a medication without talking to your prescribing clinician.